



2018

Management's Discussion and Analysis

for the nine months ended September 30, 2018

Management’s Discussion and Analysis

Belgravia Capital International Inc.

Hereinafter called “Belgravia”, the “Company”, or the “Corporation”

(Containing information up to and including November 28, 2018)

Description of Management’s Discussion and Analysis

This Management’s Discussion and Analysis (“MD&A”) should be read in conjunction with the unaudited condensed consolidated financial statements of the Corporation for the period ended September 30, 2018 and audited consolidated financial statements of the year ended December 31, 2017. This MD&A was prepared as at November 28, 2018. This MD&A contains forward-looking information and statements, which are based on the conclusions of management. The forward-looking information and statements are only made as of the date of this MD&A.

All financial information is presented in Canadian dollars unless otherwise stated. All references to a year refer to the year-ended on December 31st of that year, and all references to a quarter refer to the quarter ended on September 30th of that year. The Corporation is a reporting issuer in Alberta, British Columbia, Ontario, Saskatchewan, Manitoba, New Brunswick, Nova Scotia, Prince Edward Island, Newfoundland and the Northwest Territories.

Unless otherwise noted, financial results are reported in accordance with International Financial Reporting Standards (“IFRS”). Further details are included in Note 2 of the condensed consolidated interim financial statements for the nine months ended September 30, 2018.

Additional information related to the Corporation is available on SEDAR at www.sedar.com and on the Corporation’s website at www.belgraviacapital.ca.

Company Overview

Belgravia is a Canadian corporation focused on its three core business divisions: Incubation, Investments, and Royalty & Management Services. All three divisions are high risk and expose the Company’s shareholders to significant risk. Belgravia’s Incubation division will develop new companies in specific sectors. Belgravia Holdings, the Investments division, provides merchant banking services and invests in a portfolio of private and public companies with a focus on licit cannabis, technology, and, on an opportunistic basis, resources. The Royalty and Management Services division has developed a targeted royalty and fee income model and will provide services to support the development of early-stage companies, while taking steps to ensure it receives the water royalties owned by the Company. Belgravia is a corporation governed by the Canada Business Corporation’s Act. The shares of the Company are listed on the Canadian Securities Exchange (“CSE”) and the OTC Market under the symbols BLGV and BLGVF respectively. The Company’s registered office is located at 82 Richmond Street East, Toronto, Ontario, M5C 1P1.

The Company may obtain financing through access to public and private equity markets, debt and partnerships or joint ventures.

Belgravia owns 100% of Intercontinental Potash Corp. (“ICP”), a Canadian company previously involved in resource exploration and mine development. On November 30, 2009, the Corporation completed a reverse-takeover (“RTO”) with ICP. Legally, Belgravia is the parent of ICP, but for financial reporting purposes, Belgravia is considered to be a continuation of ICP.

Belgravia directly owns 100% of Belgravia Dermatology Inc., a Canadian company that is researching dermatology and urology products and owns 100% of two other subsidiaries that were inactive in the quarter.

Forward-Looking Statements

This MD&A includes certain statements that may be deemed “forward-looking statements” as defined under applicable securities law. Other than statements of historical facts, statements in this discussion including, but not limited to, statements that address future research and investment plans and expected or anticipated events or developments are forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include, but are not limited to, market prices, continued availability of capital and financing, general economic, market or business conditions, statements regarding planned investment activities & related returns, trends in the markets for medicinal or recreational use of cannabis and cannabinoids, the timing or assurance of the legalization of recreational cannabis, research and development activities, the potential value of royalties from water and other resources, technological advancement, competition, other statements that are not historical facts, and the risk factors identified herein. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to, changes in market trends, capital markets, the completion, results and timing of research undertaken by the Company, risks associated with natural resource assets and investments, commodity prices, industry conditions, dependence upon regulatory, environmental, and governmental approvals, the uncertainty of obtaining additional financing, and risks associated with cannabis use for medicinal or recreational purposes. Other risks that could impact the Company’s performance are described within this MD&A. These factors could also impact the Company’s performance in the future and cause variances from period to period. Although the Corporation believes the expectations expressed in any forward-looking statement are based on reasonable assumptions, investors are cautioned that any such statements are not guarantees of future performance and those actual results or developments may differ materially from those projected in the forward-looking statements.

Management's Responsibility for Financial Statements

The Company's management is responsible for the presentation and preparation of interim consolidated financial statements and the MD&A. The consolidated financial statements have been prepared in accordance with IFRS. The MD&A has been prepared in accordance with the requirements of securities regulators, including National Instrument 51-102 of the Canadian Securities Administrators.

Summary of Quarterly Results

Selected quarterly financial information of the Corporation for the quarters ended September 30, 2018 is as follows:

Table of Results for the Quarters to September 30, 2018

	Sep 30 2018	Jun 30 2018	Mar 31 2018	Dec 31 2017
Total assets	\$ 11,061,056	\$ 11,756,931	\$ 11,899,601	\$ 4,100,279
Property, plant and equipment	\$ 4,549	\$ 5,019	\$ 1,125	\$ 1,266
Working capital	\$ 10,886,925	\$ 11,684,883	\$ 11,673,562	\$ 3,476,189
Shareholders' equity (deficiency)	\$ 10,891,474	\$ 11,689,902	\$ 11,674,687	\$ 3,477,455
Interest income	\$ 27,033	\$ 2,893	\$ 25,114	\$ 539
Net income (loss)	\$ (826,428)	\$ (596,851)	\$ (3,495,591)	\$ 3,354,442
Basic income (loss) per share	\$ (0.00)	\$ (0.00)	(0.01)	0.01
Fully diluted gain (loss) per share	\$ (0.00)	\$ (0.00)	(0.01)	0.01

Selected quarterly financial information of the Corporation for the quarters ended September 30, 2017 is as follows:

Table of Results for the Quarters to September 30, 2017

	Sept 30	June 30	Mar 31	Dec 31
	2017	2017	2017	2016
Total assets	\$ 640,022	\$ 1,450,263	\$ 1,385,112	\$ 30,996,894
Property, plant and equipment	\$ 1,494	\$ 1,821	\$ 2,127	\$ 26,552,924
Working capital	\$ (38,128)	\$ 535,499	\$ 162,387	\$ 790,051
Shareholders' equity	\$ (25,344)	\$ 549,058	\$ 164,516	\$ (14,748)
Interest income	\$ 936	\$ 1,482	\$ 1,406	\$ 1,174
Net loss	\$ (553,991)	\$ (302,350)	\$(10,904,752)	\$(57,871,301)
Basic loss per share	\$ (0.00)	\$ (0.00)	\$ (0.05)	\$ (0.31)
Fully diluted loss per share	\$ (0.00)	\$ (0.00)	\$ (0.05)	\$ (0.31)

Results of Operations for the Quarter ended September 30, 2018

The Company did not generate operating revenue during the quarter ended September 30, 2018 other than management services fees. The Company also earned investment and interest income.

Office and Administration Expenses

Administration and related costs amounted to \$104,872 (2017 – \$28,039) for the quarter. This included director fees, annual general meeting, insurance, telephone, postage and courier, dues and subscriptions, stationery, repairs and maintenance, utilities and related costs. The increase is due to an increase in the Directors and Officers insurance premium, fees related to the proxy solicitation to shareholders of one of the Company's investees, director fees, and fees paid to an advisory board member of Belgravia Dermatology Inc. in the quarter.

Business development and market development spending for the quarter was \$24,563 (2017 - \$73,220). Business development costs included activities related to the search for partners as well as exploring new investment strategies, which has slowed down since the Ochoa project was sold.

Consulting fees in the quarter were \$133,060 (2017 – \$31,499); this was mostly in respect of strategy, management and capital markets consulting. This increase is due to more consulting related to capital markets, investing and the new business model. Part of the cost increase is from retaining additional consultants to provide services and to fulfil the Company's obligations under management services agreements, pursue the royalties, and assist with the proxy solicitation and legal action against one of the Company's investee companies.

Depreciation during the quarter amounted to \$470 (2017 - \$259). This relates to depreciation of computer equipment.

Fundraising activities for the quarter was \$nil (2017 – \$137,000). This amount is for expenses related to identifying and meeting with potential investors. The company was not actively pursuing any financings in the quarter.

Investor relations cost in the quarter was \$43,040 (2017 – \$28,248). This amount is for expenses related to offsite events, conferences and roadshows, meetings with shareholders and potential shareholders, and other investor relations activities.

Professional fees of \$157,004 (2017 – \$180,284) for the quarter were incurred in respect of auditing costs, other accounting costs, and legal costs. These costs were lower because the accrual for the 2018 audit has decreased due to

the changes in the operations of the Company. Most legal fees in this quarter are related to the proxy solicitation to shareholders of one of the Company's investee companies and legal action against that same company.

Regulatory fees including transfer agent and filing fees and CSE fees were \$18,409 (2017 - \$11,205). This is for transfer agent and other stock exchange listing fees and securities filings.

Rent and storage in the quarter were \$30,180 (2017 - \$25,573).

Research costs in the quarter were \$77,353 (2017 - \$nil). This increase was because the research activities of Belgravia Dermatology Inc. did not start until 2018.

Share-based compensation for the quarter was \$nil (2017 - \$nil) due to no stock options being granted in the quarter.

Travel, including related costs, for the quarter amounted to \$11,283 (2017 - \$29,090) and were composed of such costs not specifically related to investor relations and business development. The decrease is largely due to the sale of the Ochoa project resulting in less travel to the USA.

Wages and benefits for the quarter amounted to \$179,789 (2017 - \$169,693). This amount included the compensation and employment related costs of the President and Chief Executive Officer, Chief Financial Officer, Controller, Vice President, management and administrative staff. The increase is due salary raises for employees.

Management services revenue for the quarter was \$185,000 (2017 - \$nil). The increase is because the company started providing these management services and earning this revenue in late 2017.

Investment loss for the quarter was \$218,861 (2017 - \$16,301) including a \$7,714 (2017 - \$nil) loss from selling some investment shares, unrealized investment loss on equity and debt of \$313,265 (2017 - \$16,301) and unrealized investment gains from warrants that were included in investment units for \$102,118 (2017 - \$nil). Merchant banking activities began in mid-2017 and increased dramatically in early 2018 after the proceeds from the sale of the Ochoa project were received.

Interest income for the quarter was \$27,033 (2017 - \$936). The increase is because the company had excess uninvested cash resulting from the proceeds of the sale of the Ochoa project, the exercise of warrants and stock options, and the equity private placement financing that occurred in early 2018. Also, the Company earned higher interest on a new bridge loan to one of its investees that was paid in common shares of that investee.

Derivative gain for the quarter of \$nil (2017 - \$158,924) related to warrants being issued in a currency other than the functional currency of the Company. The decrease is because the functional currency was changed back to Canadian currency on October 31, 2017.

Investment Portfolio

The Company invests in a diversified portfolio of private and public companies and money market & bond funds with a focus on healthcare/biotech, technology, licit cannabis and, on an opportunistic basis, resources with a goal to provide a risk-appropriate return to its shareholders through capital gains in accordance with the Company's investment guidelines.

During the quarter ended September 30, 2018, the Company recorded an unrealized loss of \$313,265 (2017 - \$17,500) for equity, debt and mutual fund investments and an unrealized gain of \$102,118 (2017 - \$nil) for warrants.

During the quarter ended September 30, 2018, the Company sold certain of its investments for proceeds totalling \$4,897,031 (2017 - \$nil) and recognized a loss of \$7,714 (2017 - \$nil).

As at September 30, 2018, fair value of the investments was \$6,190,350 (Dec. 31, 2017 - \$983,514). This includes value of debt and equity investments of \$5,353,025 (Dec.31, 2017 - \$588,796) and value of warrants of \$837,324 (Dec. 31, 2017 - \$394,718). The Company has made diversified investments in the common shares of public and private companies in the areas of technology, blockchain, legal cannabis and mineral resources with a total approximate initial investment of \$5.2 million. The value of investments was much lower in 2017 because the Company did not start its merchant banking activities until late 2017.

Belgravia currently holds twenty investments in fourteen public and six private companies. Subsequent to September 30, 2018, Zonetail Inc., Halo Labs Inc., and Plus Products Holdings became public companies. The value of the investments in private companies might only be realized if those companies are sold or if they go public to create liquidity. Updates are provided directly below for five core holdings.

Tartisan Nickel Corp. (CSE:TN):

Belgravia continues its litigation against Tartisan Nickel Corp. (“Tartisan”), a company in which Belgravia holds 7,624,000 common shares, and D. Mark Appleby. In the lawsuit, Belgravia claims for damages in the amount of \$750,000 for negligent misrepresentation and breach of contract.

Belgravia entered into a management services agreement with Tartisan (the “MSA”) to provide services and for which Tartisan was required to pay Belgravia amounts totalling \$150,000. Tartisan has paid only \$50,000 of this amount in breach of the MSA. These services included, but were not limited to, adding one board member, capital markets advisory, digital marketing, and corporate governance.

A statement of defence and counterclaim seeking \$1,050,000 in damages plus costs of the action was received by the Company on July 19, 2018.

Belgravia has been aggressively advancing the legal claim. Discoveries were scheduled for November 2018, but Tartisan has postponed it until February 2019.

On August 7, 2018, Belgravia issued an open letter to the shareholders of Tartisan and commenced a proxy solicitation filed on August 22, 2018, a Dissident GREEN Proxy and Circular notifying Tartisan shareholders that Belgravia would attempt to replace the entire board of directors at the annual general and special meeting of shareholders scheduled for September 17, 2018. Belgravia has a contractual right to a board seat in a management services agreement, which Tartisan has failed to deliver. Currently, Tartisan has only 3 directors. One director resigned following the AGM. Belgravia was attempting to add professionals to the board, however the attempt was unsuccessful. The cost of this endeavor was mitigated by contingent success fees from legal advisors.

R&D Pharma Corp.:

Belgravia owns 4 million common shares (approximately 9% of the outstanding shares) of R&D Pharma Corp. (“R&D”), a private Canadian corporation developing a vertically integrated legal medicinal cannabis business in Jamaica. R&D is one of the few medical cannabis cultivation companies on the island, which has a full Tier 3 Cultivator’s Licence. R&D is building its cultivation facilities and establishing international distribution relationships.

Belgravia is providing the company with business, finance, accounting and governance advisory services under a management services agreement. Belgravia is providing management services of its CFO under the terms of the

management services agreement. Other Belgravia consultants and management have advised and assisted in various corporate mandates of R&D. Belgravia has received \$190,000 in management fees year to date for the services it has provided in Canada and Jamaica. Belgravia has incurred expected costs in providing the services in line with its budget. Belgravia has provided over 500 hours of professional services to R&D in anticipation of a going-public transaction.

On November 1, 2018, Weekend Unlimited Inc. ("Weekend") (CSE: YOLO) a lifestyle cannabis company, announced that it has entered into an arms-length binding letter of intent to add to its brand portfolio with the acquisition of R&D. Weekend will issue to the shareholders of R&D a total of 50,000,000 common shares and 25,000,000 warrants. Each warrant entitles the holder to subscribe for an additional share for \$0.35 for a period of 2 years from closing, subject to the right of the Company to accelerate expiry date upon 30 days' notice if its common shares trade at \$0.75 or higher for 10 consecutive business days any time after 4 months from closing. Pending closing, Weekend has advanced CDN \$2.4 million on a secured loan basis to R&D for construction costs. While in the final due diligence stage, there is no certainty that this transaction will close, or if it does close, will close on the current terms as agreed between the parties.

Zonetail Inc.:

Belgravia owns 4,749,999 shares of Zonetail Inc., representing approximately 7% of the outstanding common shares. Zonetail is the world's first free mobile app and platform, custom branded to hotels, which connects guests to the full range of hotel services and businesses in the surrounding neighbourhood. Zonetail recently closed its previously announced brokered private placement of 11,130,092 subscription receipts of for gross proceeds of \$2,003,416 and recently went public.

Belgravia is providing advisory services to Zonetail in respect corporate governance, business development, digital marketing and web development pursuant to a management services agreement. One Belgravia employee and two consultants of Belgravia are active in providing these management services. Year to date Belgravia has received \$125,000 in management fees. There is an outstanding bridge loan of \$325,000 owed to Belgravia from Zonetail. Belgravia has provided over 300 hours of professional services to Zonetail in anticipation of its reverse takeover.

Blackrock Gold Corp. (TSX-V:BRC):

Belgravia owns 8,280,000 shares of Blackrock Gold Corp. ("Blackrock") representing approximately 19% of the outstanding common shares. Blackrock's main asset is the Silver Cloud project in Nevada.

Nexus Gold Corp. (TSX-V:NXS):

Belgravia owns 1,650,000 shares of Nexus Gold Corp. ("Nexus") representing approximately 7% of its outstanding shares. Nexus is operating three gold exploration projects in Burkina Faso, West Africa.

Belgravia also entered into a management services agreement with Nexus. Belgravia's senior executives are working with Nexus to identify growth and acquisition opportunities. One Belgravia employee and two consultants are providing capital markets advisory, corporate development and digital marketing services. Year to date Belgravia has received \$240,000 for the services it has provided and will continue to provide into Q2 of 2019.

Royalty & Management Services Division:

For the 9 months ending September 30, 2018, Belgravia has been awarded management service contracts with a value of \$1,015,000, of which \$659,750 (2017 - \$nil) has been recognized as revenue. These revenues increased because

the Company was not offering such services in the first half of 2017. These services are in respect to business strategy, capital markets, public disclosure, governance, accounting, finance, and corporate personnel. Belgravia generally offers these advisory services, mentoring, and access to the Belgravia's network to its investees in order to help these companies succeed and develop, which results in increases to the value of Belgravia's investment. The Company uses consultants as needed to provide services under these management services agreements.

There is no assurance that the Company will continue to earn management services revenue as each agreement is negotiated on a one-off basis and generally for a period of less than 12 months. These revenues come from high risk companies that may default on payments under the management services agreements.

The Company holds an interest in up to USD\$12.2 million of anticipated water and mineral royalties from its previously-owned Ochoa project. Belgravia is actively pursuing these royalties through the retention of a legal advisor. No royalties have been received to date and there is no assurance that these royalties will ever be received.

Incubator Division Projects

The Company is doing research with the intention to develop and market healthcare products, none of which are reportable segments at September 30, 2018 due to the types and amount of expenditures to date. No costs have been capitalized as intangible assets on the statement of financial position because the research and evaluation is not complete and the Company has uncertainty about:

- i. the technical feasibility of completing the intangible asset so it will be available for use or resale;
- ii. its intention to complete and its ability to use or sell the asset;
- iii. how the asset will generate future economic benefits; and
- iv. the availability of resources to complete the asset.

Belgravia Dermatology Inc. ("BD")

The mission of BD is to develop cannabis-sourced molecules for use as active pharmaceutical ingredients in natural health products and in medications for dermatological and urological conditions. The indications of interest for dermatology include unmet medical needs in acne, atopic dermatitis, and psoriasis.

BD has researched studies in the area of cannabis-sourced possible active pharmaceutical ingredients for the treatment of acne. Activity has been found for various cannabinoids, terpenoids, flavonoids, and related synthetic molecules that may affect endocannabinoid targets including CB-1, CB-2, the TRPV ion channels, and other cell receptors. Activation of these receptors would affect apoptosis, sebocyte differentiation, sebum production, and anti-infection cellular activities. All of the effects are important in the aetiology and therefore treatment of acne.

During the Quarter, the Company carried out further work to complete the planning of initial product development for both certain dermatological conditions and certain urologic conditions. The work was carried out with input from the directors of Belgravia Dermatology including Dr. Sam Hanna and Sidney Himmel. The initial dermatological conditions for which product development is planned includes a natural health product for acne, an ethical drug for acne, and also an ethical drug for pruritus. In the area of urology, it has been determined that the likely products will include a natural health product for benign prostate hypertrophy and an ethical drug for overactive bladder.

The establishment of commercial relationships is underway with a regulatory consulting group, a compounding pharmaceutical group, a licensed narcotics dealer, and a contract research organization. These relationships have not yet been completed and are pending the finalization of the capital budget and the allocation of capital. The capital budgets for the development of the natural health products are significant in comparison to working capital, and the company has determined that it should search for joint venture partners to assist in the financing of these operations. Discussions are underway with potential joint venture partners.

Initial capital will be required for the following:

- Finalization of formulation for acne natural health and ethical drug development in respect of acne;
- Finalization of formulation in respect of natural health products for benign prostate hypertrophy;
- In-licensing of specific drug delivery mechanisms for each of the above which will meet the needs for minimizing pharmacokinetic complexity and minimizing systemic risks;
- Obtaining of pure medical grade active pharmaceutical ingredients;
- Storing and testing active pharmaceutical ingredients for physical characterization;
- Studying the chemistry of the drug delivery systems with respect to the active pharmaceutical ingredients;
- Discussion and planning of product development with regulatory consultants and Health Canada, and in particular determining what pre-clinical testing may be required.

The estimated costs for the above activities will be in the range of \$750,000. During these stages in is also intended that Intellectual Property (“IP”) will be prosecuted. The estimated cost of IP development is in the range of \$400,000. The Company plans to expend additional funds the advance this project subject to the results of research and development activities going forward. The total costs required to obtain saleable urology or dermatological cannabis related products are estimated at a minimum of \$2 million to \$5 million per product. Therefore, additional capital will need to be raised, either through equity markets, or by way of joint venturing with other parties.

Independent of the specific joint venture partners selected, it is anticipated that most of the development will be carried out through outsourcing. It is intended that the active pharmaceutical ingredients will include at least two different molecular entities in each medical condition, and these will be any two or more of natural plant cannabinoids, terpenoids, or related molecules. The basic classes of molecular entities have been selected, but the finalization is dependent upon additional review by medical consultants.

Natural Health Products are regulated by the Natural and Non-prescription Health Products Directorate in Canada. Ethical drugs are regulated by the Therapeutic Products Directorate of Health Canada. At present, applications for approval of potential phytocannabinoid medical products in respect of which medical claims are made must be made in accordance with the regulations of the Health Products Directorate. The status of cannabidiol is currently that of an ethical drug active pharmaceutical ingredient in Canada. However, studies can be carried out under the Cannabis Act if a research license is obtained. It is anticipated that initial research will be carried out by consultants. The development of cannabis-related products in the dermatology space involves operating in highly regulated industries. Regulations include those written in respect of the Controlled Drugs and Substances Act, including the Access to Cannabis for Medical Purposes Regulations, the Narcotic Control regulations, the regulations of the Natural and Non-Prescription Health Products Directorate, and also the regulations of the Therapeutic Products Directorate under the Food and Drugs Act and Regulations.

For the nine months ended September 30, 2018, the following expenditures have been made on behalf of BD:

	At September 30, 2018
Administrative costs	\$ 89,007
Research costs	\$169,353
Capitalized intangible assets	\$ 0
Total	\$258,360

Financings

During the nine months period ended September 30, 2018, the Company issued the following common shares:

- On January 10, 2018, the Company issued 133,990,000 units pursuant to a private placement at \$0.05 per unit for gross proceeds of \$6,699,500. Each unit consists of one common share of the Company and one

common share purchase warrant. Each warrant entitles the holder to acquire one common share of the Company for \$0.18 per share until January 10, 2019, provided that if, at any time after the date which is four months and one day following the closing date, the volume weighted average price of the common shares is equal to or exceeds \$0.21 for 18 consecutive trading days, the Company may accelerate the expiry date of the warrants, in which event the warrants will expire upon the date (the "Accelerated Expiry Date") which is 30 days following of a press release by the Company announcing the Accelerated Expiry Date. The Company issued 3,649,200 finder's warrants to certain eligible arm's length parties entitling the holder to acquire one Common Share for a period of 12 months at an exercise price equal to \$0.19

- In the nine months period ended September 30, 2018, the Company issued 2,400,000 shares at an average price of \$0.095 for gross proceeds of \$228,000 pursuant to the exercise of stock options.
- In the nine months period ended September 30, 2018, the Company issued 30,843,810 shares at \$0.08 for gross proceeds of \$2,467,505 pursuant to the exercise of warrants.
- In the nine months period ended September 30, 2018, the Company issued 280,000 shares at \$0.06 for gross proceeds of \$16,800 pursuant to the exercise of broker warrants.
- On May 24, 2018, the Company issued 5,000,000 shares at a deemed price of \$0.10 per share with a deemed value of \$500,000 as consideration to acquire 2,000,000 common shares of R&D Pharma Corp. The shares of the Company had a market price of \$0.05 on that date, so the investment was initially recorded at \$250,000 and an immediate unrealized gain of \$250,000 was recorded on the transaction date.
- On October 17, 2018, Belgravia announced an amendment to the terms of certain share purchase warrants set to expire January 10, 2019. The date of expiration has been extended to May 10, 2019 and the exercise price has been reduced to \$0.06. The extension and price reduction will not apply to the 3,649,200 broker warrants issued on January 10, 2018. The expiration of all warrants will be accelerated to 30 days if the share price reaches or exceeds \$0.08 for ten consecutive trading days ("Acceleration Trigger"), with such 30-day period starting seven-days after the Acceleration Trigger. All other terms of the Warrants remain unchanged.

During the nine months period ended September 30, 2017, the Company issued the following common shares:

- On January 24, 2017, the Company issued 200,000 shares at \$0.08 for gross proceeds of \$16,000 pursuant to the exercise of warrants.
- On March 1, 2017, the Company issued 6,573,333 units pursuant to a non-brokered offering at \$0.105 per unit for gross proceeds of \$690,200. Each unit consists of one common share of the Company and one-half common share purchase warrant. Each warrant entitles the holder to acquire one common share of the Company for \$0.16 per share until March 1, 2018. In November 2017, the exercise price of these warrants was amended to be \$0.08 per share. The Company paid finder's fees to certain qualified eligible persons assisting the Company in the offering in the aggregate amount of \$504.
- On April 5, 2017, the Company issued 31,500 shares at \$0.065 for gross proceeds of \$2,048 pursuant to the exercise of broker warrants.
- On May 3, 2017, the Company issued 785,089 shares at \$0.065 for gross proceeds of \$51,031 pursuant to the exercise of broker warrants.
- On June 27 and June 28, 2017, the Company issued an aggregate of 16,738,808 units pursuant to a non-brokered offering at \$0.05 per unit for gross proceeds of \$836,940. Each unit consists of one common share of the Company and one common share purchase warrant. Each whole warrant entitling the holder to acquire one common share of the Company for \$0.08 per share until June 28, 2018, subject to certain accelerated expiry provisions. The Company paid finder's fees to certain qualified eligible persons assisting the Company in the offering in the aggregate amount of \$14,000 and issued 280,000 broker warrants entitling the broker to acquire one Common Share for a period of 12 months at an exercise price equal to \$0.06.

Liquidity and Capital Resources at September 30, 2018

At September 30, 2018, the Corporation's working capital was \$10,886,925 (2017 – negative \$38,128). Investments in private and junior public companies that are included in working capital may not be liquid in the short term and present greater risk to Belgravia and its shareholders. The sources of cash in the period included cash from the Settlement Agreement with ICP(USA), issuing common shares, warrants exercised, stock options exercised, management services consulting fees, proceeds from the sale of investments, and interest earned on cash in the bank accounts.

The consolidated financial statements for the period ended September 30, 2018 have been prepared on a going concern basis, which contemplates the realization of assets and the discharge of liabilities in the normal course of business for the foreseeable future. This MD&A does not give effect to any adjustment which would be necessary should the Corporation be unable to continue as a going concern and therefore, be required to realize its assets and discharge its liabilities in other than the normal course of business and at amounts different from those reflected in this MD&A.

Transactions with Related Parties

In July 2015, the Company signed a Termination and Settlement Agreement that included a severance payment to be paid to the former President and Chief Executive Officer: The full amount of the severance of \$2,100,000 was expensed during the year ended December 31, 2015. As at September 30, 2018, the balance of employment liability is \$nil (2017- \$570,000), after paying the remaining balance in January 2018.

During the nine months period ended September 30, 2018, the Company entered into the following transactions with related parties:

- a) Paid or accrued short-term employee benefits of \$666,500 (2017 - \$360,011), of which \$501,500 (2017 - \$186,000) was paid to Mehdi Azodi, \$nil (2017 - \$62,011) was paid to Ken Kramer, and \$165,000 (2017 - \$112,000) was paid to Kevin Strong.
- b) Paid consulting fees of \$nil (2017 - \$115,754) to Graham Wheelock.
- c) Paid or accrued directors' fees, included in administrative costs, of \$240,500 (2017 - \$96,000), of which \$64,250 (2017 - \$27,000) was for Ernest Angelo, \$57,500 (2017 - \$13,500) was for Knute Lee, \$57,500 (2017- \$13,500) was for Pierre Pettigrew, \$61,250 (2017 - \$37,500) was for John Stubbs, and \$nil (2017 - \$4,500) was for Grant Sawiak.
- d) Incurred share-based compensation in the form of stock options valued at \$1,952,868 (2017 - \$273,927), of which \$578,193 (2017 - \$42,561) was to Mehdi Azodi, \$286,377 (2017 - \$42,561) was to John Stubbs, \$396,131 (2017 - \$26,600) was to Pierre Pettigrew, \$250,448 (2017 - \$42,561) was to Ernest Angelo, \$248,791 (2017 - \$26,600) was to Knute Lee, \$192,928 (2017- \$17,227) was to Kevin Strong, \$nil (2017- \$49,217) to Sidney Himmel, and \$nil (2017 - \$26,600) was to Grant Sawiak.
- e) Included in accounts payable as at September 30, 2018 is \$58,906 (2017- \$83,370) due to key management personnel, which includes officers and directors and corporations controlled by officers and directors.
- f) Included in prepaid expenses as at September 30, 2018 is \$7,958 (2017- \$49,363) prepaid to key management personnel, which includes officers and directors and corporations controlled by officers and directors.

Key management personnel compensation (including senior officers and directors of the Company):

	Nine-month ended	
	September 30, 2018	September 30, 2017
Short-term benefits *	\$ 666,500	\$ 360,011
Consulting fees	-	115,754
Directors' fees **	240,500	96,000
Share-based compensation	1,952,868	273,927
Total remuneration	\$ 2,859,868	\$ 845,692

* Amounts are included within wages and benefits on the statement of loss and comprehensive loss.

** Amounts are included within administration on the statement of loss and comprehensive loss.

Financial Instruments

International Financial Reporting Standards 7, Financial Instruments: Disclosures, establishes a fair value hierarchy that reflects the significance of the inputs used in making the measurements. The fair value hierarchy has the following levels:

Level 1 - quoted prices (unadjusted) in active markets for identical assets or liabilities;

Level 2 - inputs other than quoted prices included in Level 1 that are observable for the asset or liability, either directly (i.e. as prices) or indirectly (i.e. derived from prices); and

Level 3 - inputs for the asset or liability that are not based on observable market data (unobservable inputs).

The Company's financial instruments include cash and cash equivalents, investments, receivables, accounts payable and accrued liabilities.

Cash is measured at fair value using level one as the basis for measurement in the fair value hierarchy. Investments in public companies, mutual funds, money market funds and fixed income funds are measured at level one while investments in warrants and private companies are measured at level three. The warrant liability and embedded derivative are categorized as level three. The carrying value of receivables, accounts payable and accrued liabilities and employment liability approximate fair value because of the short-term nature of these instruments.

Other

Outstanding Share data as at November 28, 2018:

(a) Authorized and issued share capital at November 28, 2018:

Class	Par Value	Authorized	Issued Number
Common	No Par Value	Unlimited	411,354,656 *

(*) Included in 411,354,656 shares is 9,562,140 Treasury Shares that the Company purchased and returned to treasury pursuant to an issuer bid subsequent to September 30, 2018

(b) Summary of Options outstanding as at November 28, 2018:

Number of Options	Exercise Price (CAD)	Expiry Date
250,000	\$ 0.12	November 14, 2019
500,000	\$ 0.10	November 24, 2019
350,000	\$ 0.10	February 14, 2020
200,000	\$ 0.10	March 1, 2020
9,900,000	\$ 0.18	January 10, 2021
1,000,000	\$ 0.18	January 16, 2021
250,000	\$ 0.14	January 23, 2021
250,000	\$ 0.14	January 30, 2021
100,000	\$ 0.13	February 9, 2021
1,250,000	\$ 0.08	April 16, 2021
250,000	\$ 0.08	April 30, 2021
9,100,000	\$ 0.08	June 6, 2021
300,000	\$ 0.08	July 12, 2021
3,900,000	\$ 0.10	February 14, 2022
7,400,000	\$ 0.14	January 23, 2023
4,000,000	\$ 0.08	April 16, 2023
39,000,000		

(c) Warrants outstanding as at November 28, 2018:

In October 2018, the terms of outstanding warrants set to expire January 10, 2019 were modified. The date of expiration has been extended to May 10, 2019 and the exercise price has been reduced from \$0.18 to \$0.06.

The Company had warrants outstanding, enabling the holders to acquire the following number of common shares:

Number of Warrants	Exercise Price	Expiry Date
133,990,000	0.06	May 10, 2019
133,990,000		

(d) Broker warrants outstanding as at November 28, 2018:

The Company had broker warrants outstanding, enabling the holders to acquire the following number of common shares:

Number of Broker Warrants	Exercise Price	Expiry Date
3,649,200	0.19	January 10, 2019
3,649,200		

Accounting Principles

The financial statements have been prepared in accordance with IFRS.

The policies and estimates are considered appropriate under the circumstances but are subject to judgments and uncertainties inherent in the financial reporting process. See also Note 2 in the condensed consolidated interim financial statements for the nine months period ended September 30, 2018 and also the consolidated financial statements for the year ended December 31, 2017 for additional detail on accounting principles.

Foreign currency translation

The consolidated interim financial statements are presented in Canadian dollar. Prior to November 1, 2017, the functional currency of the Company and its subsidiaries was the U.S. dollars. The Company and its subsidiaries' functional currency changed on a prospective basis from the U.S. dollar to Canadian dollar to better reflect the Company's business activities.

Transactions in foreign currencies are translated into the entity's functional currency at the exchange rates at the date of the transactions. Monetary assets and liabilities of the Company's operations denominated in a currency other than the Canadian dollar are translated using the exchange rates prevailing at the date of the statement of financial position. Non-monetary items that are measured in terms of historical cost in a foreign currency are translated using the exchange rates in effect at the date of the underlying transaction, except for depreciation related to non-monetary assets, which is translated at historical exchange rates. Exchange differences are recognized in the statements of loss and comprehensive loss in the year in which they occur.

New standards, amendments and interpretations:

Effective January 1, 2018

IFRS 9 - Financial Instruments: Classification and Measurement. IFRS 9 is a new standard that will replace IAS 39. IFRS 9 introduces new requirements for the classification and measurement of financial instruments as well as de-recognition of financial instruments. IFRS 9 has two measurement categories for financial assets: amortized cost and fair value. All equity instruments are measured at fair value and a debt instrument is measured at amortized cost only if the entity is holding it to collect contractual cash flows in the form of principal and interest otherwise it is at fair value through profit or loss ("FVTPL"). The adoption of IFRS 9 did not have an impact on the Company's consolidated financial statements.

IFRS 15 - Revenue from Contracts with Customers. IFRS 15 establishes the principles that an entity shall apply to report useful information to users of financial statements about the nature, amount, timing, and uncertainty of revenue and cash flows arising from a contract with a customer. The adoption of IFRS 15 did not have an impact on the Company's consolidated financial statements.

Effective January 1, 2019

IFRS 16 – Leases. IFRS 16 is a new standard that sets out the principles for recognition, measurement, presentation, and disclosure of leases including guidance for both parties to a contract, the lessee and the lessor. The new standard eliminates the classification of leases as either operating or finance leases as is required by IAS 17 and instead introduces a single lessee accounting model. Management anticipates that this standard will be adopted in the Company's financial statements for the period beginning January 1, 2019 and is currently evaluating the potential impact of the adoption of IFRS 16.

Risks and Uncertainties

Credit risk

The Company's credit risk is primarily attributable to cash and cash equivalents and receivables. The Company has no significant concentration of credit risk arising from operations. Cash is held at reputable financial institutions, from which management believes the risk of loss to be remote. Receivables consist primarily of amounts due from government agencies, from loans outstanding to employees and consultants, and from management services clients, which the Company believes will be fully collected, however there is a risk of non-payment from the management services clients.

Liquidity risk

As at September 30, 2018, the Company had a cash and cash equivalents balance of \$4,717,131 to settle current liabilities of \$169,582. The Company is not subject to liquidity risk.

Interest rate risk

The Company has cash balances subject to fluctuations in the prime rate. The Company's current policy is to invest some of excess cash in investment-grade highly liquid demand deposit certificates issued by its banking institutions. The Company periodically monitors the investments it makes and is satisfied with the credit ratings of its banks. Management believes that interest rate risk is remote as cash deposits are payable on demand and the Company currently does not carry interest bearing debt at floating rates. Fluctuations in interest rates may impact the value of the Company's investments in publicly traded common shares and investments in floating rate debt and deposits.

Foreign currency risk

The Company's functional currency is the Canadian dollar; however, there are transactions in U.S. dollars and the Company keeps some of its cash in US currency. The Company is exposed to financial risk arising from fluctuations in foreign exchange rates and the degree of volatility in these rates. The Company does not use derivative instruments to reduce its exposure to foreign currency risk. A 10% change in the foreign exchange rate would have had an approximate \$170,000 impact on foreign exchange gain or loss.

Market and Investment risk

Market risk is the risk that the fair value of, or future cash flows from, the Company's financial instruments will fluctuate due to changes in market prices. The value of financial instruments can be affected by changes in interest rates, foreign exchange rates, and equity and commodity prices. The Company is exposed to market risk in trading its investments and unfavourable market conditions could result in dispositions of investments at less than favourable prices. The amounts at which the Company's publicly-traded investments could be disposed of currently may differ from their carrying values based on market quotes, as the value at which significant ownership positions are sold is often different than the quoted market price due to a variety of factors such as premiums paid for large blocks or discounts due to illiquidity. Additionally, current market prices may differ significantly from the historical prices used to calculate fair value for the purposes of the Company's financial statements. The Company's investments are accounted for at fair value and are sensitive to changes in market bid prices, such that market trends and changes in market prices result in a proportionate change in the carrying value of the Company's investments.

The Company's results of operations and financial condition are dependent upon the market value of the securities that comprise the Company's investment portfolio. Market value can be reflective of the actual or anticipated operating results of the Company's portfolio companies and/or the general market conditions that affect the sectors in which the Company invests. The Company's investments are primarily concentrated in the junior healthcare, natural resource, and technology industries, which results in exposure to higher volatility and risk than broader market investments and indexes. The value of any or all of the Company's investments could become zero in the future. There are various factors that could have a negative impact on investee companies and thereby have an adverse effect on the Company. Additionally, the Company's investments are mostly in small-cap businesses which the Company believes exhibit potential for growth and sustainable cash flows but which may not ever mature or generate the returns the Company expects or may require a number of years to do so. Technology and resource companies may never achieve success. This may create an irregular pattern in the Company's revenues (if any). Macro factors such as fluctuations in commodity prices and global political, economic and market conditions could have an adverse effect on one or more sectors to which the Company is exposed, thereby negatively impacting one or more of the portfolio companies concurrently. Company-specific risks could have an adverse effect on one or more of the Company's portfolio companies at any point in time. Company-specific and industry-specific risks which materially adversely affect the Company's investments may have a materially adverse impact on its operating results.

The Company holds investments in private and publicly-traded equity securities. Market prices for equity securities are subject to fluctuation and consequently the amount realized in the subsequent sale of an investment may significantly differ from the reported market value. Investments in securities of public companies are subject to volatility in the share prices of the companies. There can be no assurance that an active trading market for any of the subject shares is sustainable. The trading prices of the subject securities could be subject to wide fluctuations in response to various factors beyond the control of the Company, including quarterly variations in the subject entities' results of operations, changes in earnings (if any), estimates by analysts, conditions in the industry of the subject companies and general market or economic conditions. In recent years, equity markets have experienced extreme price and volume fluctuations. These fluctuations have had a substantial effect on market prices, often unrelated to the operating performance of the specific companies. Such market fluctuations could adversely affect the market price of the Company's investments and significantly negatively impact upon the Company's operating results

Some investments may not be very liquid and dispositions may take time or may be sold at less than market prices. The amounts at which the Company's private company investments could be disposed of currently may differ from their carrying values since there is no active market to dispose of these investments. Investments in private issuers cannot be resold without a prospectus, an available exemption or an appropriate ruling under relevant securities legislation and there may not be any market for such securities. These limitations may impair the Company's ability to react quickly to market conditions or negotiate the most favourable terms for exiting such investments. Investments in private issuers may offer relatively high potential returns, but will also be subject to a relatively high degree of risk. There can be no assurance that a public market will develop for any of the Company's private company investments or that the Company will otherwise be able to realize a return on such investments. The Company also invests in illiquid securities of public issuers. A considerable period of time may elapse between the time a decision is made to sell such securities and the time the Company is able to do so, and the value of such securities could decline during such period. Illiquid investments are subject to various risks, particularly the risk that the Company will be unable to realize the Company's investment objectives by sale or other disposition at attractive prices or otherwise be unable to complete any exit strategy. In some cases, the Company may be prohibited by contract or by law from selling such securities for a period of time or otherwise be restricted from disposing of such securities. Furthermore, the types of investments made may require a substantial length of time to liquidate.

Investments may include debt instruments and equity securities of companies that Belgravia does not control. These instruments and securities may be acquired by the Company in the secondary market or through purchases of securities from the issuer. Any such investment is subject to the risk that the company in which the investment is made may make business, financial or management decisions with which the Company does not agree or that the majority stakeholders or the management of the company may take risks or otherwise act in a manner that does not serve the Company's interests. If any of the foregoing were to occur, the values of investments could decrease and the Company's financial condition, results of operations and cash flow could suffer as a result.

A 10% change in the fair values of the Company's investments at September 30, 2018 would have an \$619,035 impact on results from operations.

Operating History and Expected Losses

The Corporation has a limited history of operations and no material earnings to date and there can be no assurance that the business of the Corporation will be successful or profitable. No dividends have been paid to date. Payment of any future dividends, if any, will be at the discretion of the Company's board of directors.

The Company expects to make significant investments in its subsidiaries in order to develop healthcare products, undertake marketing efforts, improve its operations, and conduct research and development. As a result, start-up operating losses are expected in these subsidiaries and such losses may be greater than anticipated, which could have a significant effect on the long-term viability of the Company. As these projects are at an early stage, they may continue to have negative operating cash flows. Without the injection of further capital and the development of revenue streams from its business, the Company may continue to have negative operating cash flows until it can be sufficiently developed to commercialize.

The Corporation may need additional funding to complete its short and long-term objectives. The ability of the Corporation to raise such financing in the future will depend on the prevailing market conditions, as well as the business performance of the Corporation. Global financial conditions are subject to high volatility, thus access to public financing may be negatively impacted. There can be no assurances that the Corporation will be successful in its efforts to raise additional financing on terms satisfactory to the Corporation. The market price of the Corporation's shares at any given point in time may not accurately reflect the long-term value. If adequate funds are not available or not available on acceptable terms, the Corporation may not be able to take advantage of opportunities, to develop new projects or to otherwise respond to competitive pressures.

Growth Management

In executing the Company's business plan for the future, there will be significant pressure on management, operations and technical resources. The Company anticipates that its operating and personnel costs will increase in the future. In order to manage its growth, the Company will have to increase the number of its technical and operational employees

and efficiently manage its employees, while at the same time efficiently maintaining a large number of relationships with third parties.

Research and Development Activities

There is no assurance that the results of the Company's research and product development activities will be successful. The Company may abandon or modify its research and/or development efforts for many reasons including, but not limited to, changes in corporate business strategy, competition, lack of capital resources, inability to obtain necessary licenses or find partners with licenses necessary to do the remaining research and development work, unfavourable changes to regulation, negative changes in consumer attitudes towards the Company's products being developed, problems obtaining its own intellectual property or licenses necessary to produce its products, or unfavourable results of any research or development or clinical trial activities undertaken (i.e. the product does not appear to have the efficacy necessary to treat the condition).

Licenses, Patents and Proprietary Rights

The Company's success could depend on its ability to protect its intellectual property, including trade secrets, and continue its operations without infringing the proprietary rights of third parties and without having its own rights infringed.

Regulatory & Legal Risks

The Company is subject to a number of technological challenges and requirements, and can be subject to the regulations and standards imposed by applicable regulatory agencies.

Various federal, state or provincial and local laws govern the Company's business in the jurisdictions in which it operates or proposes to operate, or to which it exports or proposes to export our products, including laws and regulations relating to health and safety, conduct of operations and the production, management, transportation, storage and disposal of its products and of certain material used in its operations. Compliance with these laws and regulations requires concurrent compliance with complex federal, provincial or state and local laws. These laws change frequently and may be difficult to interpret and apply. Compliance with these laws and regulations requires the investment of significant financial and managerial resources, and a determination that it is not in compliance with these laws and regulations could harm its brand image and business. Moreover, it is impossible for the Company to predict the cost or effect of such laws, regulations or guidelines upon its future operations. Changes to these laws or regulations could negatively affect the Company's competitive position within our industry and the markets in which it operates

Reliance on Key Personnel and Advisors

The Company relies heavily on its officers and is dependent upon the services of key executives, including the Chief Executive Officer. The loss of their services may have a material adverse effect on the business of the Company. There can be no assurance that one or all of the employees of, and contractors engaged by, the Company will continue in the employ of, or in a consulting capacity to, the Company or that they will not set up competing businesses or accept positions with competitors. There is no guarantee that certain employees of, and contractors to, the Company who have access to confidential information will not disclose the confidential information.

Litigation

The Company may become party to litigation from time to time in the ordinary course of business which could adversely affect its business. Should any litigation in which the Company becomes involved be determined against the Company, such a decision could adversely affect The Company's ability to continue operating and the value of the common shares of The Company and could use significant resources. Even if the Company is involved in litigation and wins, litigation can redirect significant Company resources, including the time and attention of management and available working capital. Litigation may also create a negative perception of the Company's brand.

Other risks

To the extent of the holdings of the Company through its subsidiaries, the Company will be dependent on the cash flows of these subsidiaries to meet its obligations, which cash flows may be constrained by applicable taxation and other restrictions.

Certain of the directors and officers of the Corporation also serve as directors and/or officers of other companies and, consequently, there exists the possibility for such directors and officers to be in a position of conflict.

There are specific risks associated with some of the industries in which the Company invests, including legal cannabis, healthcare, technology, blockchain and natural resources.

Risks Related to the Medical Cannabis Industry

The Company has no commercial operations in the cannabis industry. The Company is not a grower or retailer of any cannabis products. The Company is a passive investor in the cannabis sector and in select circumstances may have one of its consultants or employees act as an advisor to a company operating legally in the sector.

The Legal Cannabis Market

The medical cannabis industry and market are relatively new in Canada and the U.S., and this industry and market may not continue to exist or grow as anticipated. The Company makes investments in companies and is internally creating products in a relatively new licit cannabis industry and market.

In addition to being subject to general business risks, the Company will need to build brand awareness in this industry and market through significant investments in its strategy, its production capacity, quality assurance, and compliance with regulations. These activities may not promote its products as effectively as intended, or at all. Competitive conditions, consumer preferences, patient requirements and pending patterns in this new industry and market are relatively unknown and may have unique circumstances that differ from existing industries and markets.

The Company and its investees are constrained by law in their ability to market their products in Canada.

Canadian Companies with U.S. Marijuana-Related Assets

In 2018, the Canadian Securities Administrators published Staff Notice 51-352 (Revised) *Issuers with U.S. Marijuana-Related Activities* (the “Staff Notice”), which provides specific disclosure expectations for issuers that currently have, or are in the process of developing, cannabis-related activities in the US as permitted within a particular state’s regulatory framework. All issuers with US cannabis-related activities are expected to clearly and prominently disclose certain prescribed information in required disclosure documents. Currently the activity of Belgravia Capital in the US cannabis sector is limited and its industry involvement of cannabis activities is indirect (as such term is used in the Staff Notice) through investments in entities (the “Investees”) operating in the US cannabis industry. More importantly, the Company does not operate, does not control any subsidiary that is directly engaged in the cultivation or distribution of marijuana or cannabis in accordance with a US state license. Due of the Investees cannabis operations in the US (described below), the Company is subject to the requirements of the Staff Notice.

To date Belgravia Capital has not obtained independent legal advice regarding compliance with US state regulatory boundaries, exposure and various risks from US federal laws in the states where its Investees conduct operations. For each of the Investees involved in the US cannabis industry, as discussed below in the synopsis of holdings, to the best of the Company’s knowledge, the Company is not aware of any non-compliance with applicable licensing requirements and the regulatory framework enacted by the applicable US state for any of such Investees’ business and the Company is not aware of: (i) any non-compliance by these Investees with respect to marijuana related activities, or (ii) any notices of violation with respect to any Investees’ marijuana-related activities by its respective regulatory authorities. Cannabis laws may be subject to change in the US.

Ability to Access Public and Private Capital

The Company has an ongoing banking relationship with more than one Canadian chartered bank., including TD Canada Trust.

Since the cultivation, distribution and possession of cannabis is currently illegal under U.S. federal law and the Company may invest in companies with cannabis operations in the U.S, it is possible that banks may refuse to open bank accounts for the deposit of funds from businesses involved with the cannabis industry. The inability to open or maintain bank accounts with certain institutions could materially and adversely affect the business of the Company.

The Company has historically, and continues to have, access to both public and private capital in Canada in order to support its continuing operations. The Company has had investments in cannabis-related companies who were legally licenced and allowed to operate in the United States under state law since early 2018. The Company has not had to complete any private placements or public offerings since January 2018, and various factors including risk factors related to the Company's investment in the cannabis sector could negatively impact the Company's ability to raise capital, although the sector has been liquid and capital arrangements have been recently executed for numerous companies.

Although the Company has accessed private financing in the past, there is neither a broad nor deep pool of institutional capital that is available to cannabis license holders and license applicants. There can be no assurance that additional financing, if raised privately, will be available to the Company when needed or on terms which are acceptable.

Reliance on third-party suppliers, manufacturers and contractors

Due to the uncertain and changing regulatory landscape for regulating cannabis in Canada and the United States, the Company's third-party suppliers and contractors may elect, at any time, to decline or withdraw services necessary for the Company's operations. Loss of these suppliers and contractors may have a material adverse effect on the Company's business and operational results.

Nature of The Company's Involvement in the U.S. Cannabis Industry

The Company does not conduct cannabis-related activities in the United States ("U.S.") except to the extent, if any, that holding non-controlling investments in entities directly involved in the U.S. cannabis industry constitutes conducting cannabis-related activities.

The Company has no direct involvement in the cultivation, possession or distribution of cannabis in the U.S. and does not provide goods or services to any entity that cultivates or distributes cannabis in the U.S.

The Company does not have any operational or management involvement with the companies listed below and holds less than 1% of the outstanding shares in five companies with investments or operations in the U.S.

1. Planet 13 Holdings Inc. is a CSE-listed vertically integrated cannabis company based in Nevada, with award-winning cultivation, production and dispensary operations in Las Vegas, Nevada. Planet 13's mission is to build a recognizable global brand known for world-class dispensary operations and a creator of innovative cannabis products. The Company currently invested \$170,000 to hold 212,500 shares.
2. Plus Products Holdings Inc. is a private branded cannabis products manufacturer headquartered in Palo Alto, California. It has introduced fast-acting edibles positioned for a healthy and active lifestyle audience seeking a premium cannabis experience. All products are hand-crafted with high quality ingredients without the gluten and calories found in competing edible products. Plus Products Inc. (CSE: PLUS) completed its initial public offering of 6,153,847 subordinate voting shares at a price of CAD\$3.25 per share for total gross proceeds of CAD\$20,000,000 and began trading on the CSE on October 29, 2018. The company currently invested \$100,000 to hold 83,333 shares.
3. Captor Capital Corp. is a Canadian investment firm focused on the cannabis sector listed on the Canadian Securities Exchange, the OTC, and the Frankfurt Stock Exchange. A vertically integrated cannabis company, Captor provides recreational and medical marijuana-based products to consumers via its leading brands and dispensary locations. Captor owns and operates advanced growing facilities which produce consistent high quality contaminant free marijuana for its customers, as well as other high demand cannabis based goods for consumption. Captor currently has a number of revenue generating cannabis investments including two wholly owned branded MedMen dispensaries in West Hollywood and Santa Ana, California. The Company currently invested \$200,000 to hold 1,000,000 shares.
4. Halo Labs Inc. is an Aequitas NEO Exchange Inc. listed company based out of Oregon which manufactures and sells Cannabis oil in Oregon, California and Nevada. The Company currently invested \$129,000 to hold 322,580 shares.
5. C21 Investments, a CSE-listed company, is a vertically integrated cannabis company with newly acquired operations in Oregon, U.S.A. C21's focus is to expand where it can wholly-own indoor/outdoor cultivation

operations, processing/extraction facilities, bakeries, branded products, and retail dispensaries with a large distribution network. The Company currently invested \$135,000 to hold 82,000 shares.

Violations of any federal laws and regulations could result in significant fines, penalties, administrative sanctions, convictions or settlements arising from civil proceedings conducted by either the federal government or private citizens, or criminal charges, including, but not limited to, disgorgement of profits, cessation of business activities or divestiture. This could have a material adverse effect on the Company or its investees, including its reputation and ability to conduct business, the listing of its securities on any stock exchange, its financial position, operating results, profitability or liquidity or the market price of its publicly traded shares. In addition, it is difficult for the Company to estimate the time or resources that would be needed for the investigation of any such matters or its final resolution because, in part, the time and resources that may be needed are dependent on the nature and extent of any information requested by the applicable authorities involved, and such time or resources could be substantial. The approach to the enforcement of cannabis laws may be subject to change, or may not proceed as previously outlined.

The following table is a summary of the Company's balance sheet exposure to U.S. cannabis-related activities as of September 30, 2018 via its non-controlling investments:

Current assets	\$1,086,719
Non-current assets	\$ 0
Total assets	\$1,086,719
Current liabilities	\$ 0
Non-current liabilities	\$ 0
Total liabilities	\$ 0

During the period, the Company did not incur any operating expenses related to its investments in U.S. companies in the cannabis sector or recognize any operating revenue from its involvement in the U.S. cannabis sector. The Company's statement of loss and comprehensive loss includes net realized and unrealized gains on its investments in U.S. companies in the cannabis sector during the period of \$428,415.

Compliance of United States Operations

Investees of the Company described above are subject to regulations in the U.S. states in which they operate.

The Company's minority investments in the U.S. cannabis industry will be (i) only in those states that have enacted laws legalizing cannabis; and (ii) only in those state's where the Company can comply with state (and local) laws and regulations and has the licenses, permits or authorizations to properly carry on each element of its business.

Based on the Company's investigation, the investees of the Company are in compliance with applicable licensing requirements and the regulatory framework enacted by the States of Nevada, California and Oregon.

However, the Company has not obtained legal advice, either in the form of a legal opinion or otherwise, regarding (a) compliance with applicable state regulatory frameworks; and (b) potential exposure and implications arising from U.S. federal law.

In addition, the Company will continue to ensure that its investments in the U.S. are in compliance with applicable licensing requirements and the regulatory framework enacted in such States either by way of a review of such entities licenses or affirmation certifications from management. The Company will only invest in companies that are legally operating in the relevant U.S. States. The Company will continue to monitor, evaluate and re-assess the regulatory framework.

While the Company's business activities are compliant with applicable state and local law, such activities remain illegal under United States federal law.

Overview of the cannabis industry in the US

Despite legal, regulatory and political obstacles, the U.S. cannabis industry continues to experience substantial growth. Cannabis Laws may be subject to change in the U.S.

In the U.S., 29 states and Washington D.C. have legalized medical marijuana, while nine states and Washington D.C. have also legalized adult-use cannabis. At the federal level, however, cannabis currently remains a Schedule I controlled substance under the U.S. Controlled Substance Act of 1970 (the "CSA"). Under U.S. federal law, a Schedule I drug or substance has a high potential for abuse, no accepted medical use in the United States, and a lack of accepted safety for the use of the drug under medical supervision. As such, the manufacture, importation, possession, use or distribution of cannabis products remains illegal under U.S. federal law. This has created a dichotomy between state and federal law, whereby many states have elected to regulate and remove state-level penalties regarding a substance which is still illegal at the federal level.

While technically illegal, the U.S. federal government's approach to enforcement of such laws has, at least until recently, trended toward non-enforcement. On August 29, 2013, the U.S. Department of Justice ("DOJ") issued a memorandum known as the "Cole Memorandum" to all U.S. Attorneys' offices (federal prosecutors). The Cole Memorandum generally directed U.S. Attorneys not to prioritize the enforcement of federal cannabis laws against individuals and businesses that rigorously comply with state regulatory provisions in states with strictly-regulated medical or adult-use cannabis programs. The Cole Memorandum, while not legally binding, assisted in managing the tension between state and federal laws concerning state-regulated cannabis businesses.

However, on January 4, 2018 the Cole Memorandum was revoked by the Attorney General Jeff Sessions. While this did not create a change in federal law - as the Cole Memorandum was not itself law - the revocation added to the uncertainty of U.S. federal enforcement of the CSA in states where cannabis use is regulated. Sessions also issued a one-page memorandum known as the "Sessions Memorandum." This confirmed the rescission of the Cole Memorandum and explained that the Cole Memorandum was "unnecessary" due to existing general enforcement guidance as set forth in the U.S. Attorney's Manual (the "USAM"). The USAM enforcement priorities, like those of the Cole Memorandum, are also based on the federal government's limited resources, and include "law enforcement priorities set by the Attorney General," the "seriousness" of the alleged crimes, the "deterrent effect of criminal prosecution," and "the cumulative impact of particular crimes on the community."

While the Sessions Memorandum does emphasize that cannabis is a Schedule I controlled substance and states the statutory view that it is a "dangerous drug and that cannabis activity is a serious crime," it does not otherwise guide U.S. Attorneys that the prosecution of cannabis-related offenses is now a DOJ priority. Furthermore, the Sessions Memorandum explicitly describes itself as a guide to prosecutorial discretion. Such discretion is firmly in the hands of U.S. Attorneys in deciding whether or not to prosecute cannabis-related offenses. U.S. Attorneys could individually continue to exercise their discretion in a manner similar to that displayed under the Cole Memorandum's guidance. Dozens of U.S. Attorneys across the country have affirmed their commitment to proceeding in this manner, or otherwise affirming that their view of federal enforcement priorities has not changed, although a few have displayed greater ambivalence. In Nevada, the U.S. Attorney has yet to make any comments regarding the revocation of the Cole Memorandum or indicate any changes to enforcement priorities.

Jeff Sessions is no longer U.S. Attorney General and an interim Attorney General has been appointed by the President. This change results in uncertainty regarding the future enforcement of federal controlled substance law.

Regulatory risks of cannabis industry in the U.S.

The cannabis sector is a new industry which is highly regulated, highly competitive and evolving rapidly. As such, new risks may emerge, and management of The Company may not be able to predict all such risks or be able to predict how such risks may result in actual results differing from the results contained in any forward-looking statements.

Participants in the U.S. cannabis industry will incur ongoing costs and obligations related to regulatory compliance. Failure to comply with regulations may result in additional costs for corrective measures, penalties or restrictions of operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could

have a material adverse effect on the business, results of operations and financial condition of The Company. Further, The Company may be subject to a variety of claims and lawsuits. Adverse outcomes in some or all of these claims may result in significant monetary damages or injunctive relief that could adversely affect its ability to conduct its business. The litigation and other claims are subject to inherent uncertainties and management's view of these matters may change in the future. A material adverse impact on The Company's financial statements also could occur for the period in which the effect of an unfavourable final outcome becomes probable and reasonably estimable.

The U.S. cannabis industry is subject to extensive controls and regulations, which may significantly affect the financial condition of market participants. The marketability of any product may be affected by numerous factors that are beyond the control of The Company and which cannot be predicted, such as changes to government regulations, including those relating to taxes and other government levies which may be imposed. Changes in government levies, including taxes, could reduce The Company's earnings and could make future growth uneconomic. The industry is also subject to numerous legal challenges, which may significantly affect the financial condition of The Company and which cannot be reliably predicted.

The Company does not expect to derive a large proportion of its revenues or investment gains from the U.S. cannabis industry, which industry is illegal under U.S. federal law. As a result of the conflicting views between state legislatures and the federal government regarding cannabis, cannabis businesses in the U.S. are subject to inconsistent legislation and regulation. Almost half of the U.S. states have enacted legislation to legalize and regulate the sale and use of medical cannabis without limits on THC, while other states have legalized and regulate the sale and use of medical cannabis with strict limits on the levels of THC. However, the U.S. federal government has not enacted similar legislation and the cultivation, sale and use of cannabis remains illegal under federal law pursuant to the CSA. The federal government of the U.S. has specifically reserved the right to enforce federal law in regards to the sale and disbursement of medical or adult-use use cannabis even if state law sanctioned such sale and disbursement. It is presently unclear whether the U.S. federal government intends to enforce federal laws relating to cannabis where the conduct at issue is legal under applicable state law. This risk was further heightened by the revocation of the Cole Memorandum in January 2018.

Failure to comply with regulations may result in additional costs for corrective measures, penalties or in restrictions of operations. In addition, changes in regulations, more vigorous enforcement thereof or other unanticipated events could require extensive changes to operations, increased compliance costs or give rise to material liabilities, which could have a material adverse effect on the business, results of operations and financial condition of the Company.

Further, there can be no assurance that state laws legalizing and regulating the sale and use of cannabis will not be repealed or overturned, or that local governmental authorities will not limit the applicability of state laws within their respective jurisdictions. It is also important to note that local and city ordinances may strictly limit and/or restrict the distribution of cannabis in a manner that will make it extremely difficult or impossible to transact business in the cannabis industry. If the U.S. federal government begins to enforce federal laws relating to cannabis in states where the sale and use of cannabis is currently legal, or if existing state laws are repealed or curtailed, then the Company's business would be materially and adversely affected. U.S. federal actions against any individual or entity engaged in the cannabis industry or a substantial repeal of cannabis related legislation could adversely affect the Company. There can be no assurances the federal government of the United States or other jurisdictions will not seek to enforce the applicable laws against The Company. The consequences of such enforcement would be materially adverse to the Company and the Company's business and could result in the forfeiture or seizure of all or substantially all of the Company's assets.

In addition, the export and import of medical cannabis is subject to United Nations treaties establishing country-by-country quotas and export and import permits are subject to these quotas which could limit the amount of medical cannabis the Company can export to any particular country.

Cannabis-related products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources.

Anti-Money Laundering Laws and Regulations

The Company is subject to a variety of laws and regulations in Canada and the U.S. that involve money laundering, financial recordkeeping and proceeds of crime, including the U.S. Currency and Foreign Transactions Reporting Act

of 1970 (commonly known as the Bank Secrecy Act), as amended by Title III of the Uniting and Strengthening America by Providing Appropriate Tools Required to Intercept and Obstruct Terrorism Act of 2001 (USA PATRIOT Act), the Proceeds of Crime (Money Laundering) and Terrorist Financing Act (Canada), as amended and the rules and regulations thereunder, and any related or similar rules, regulations or guidelines, issued, administered or enforced by governmental authorities in the U.S. and Canada. Further, under U.S. federal law, banks or other financial institutions that provide a cannabis business with a checking account, debit or credit card, small business loan, or any other service could be found guilty of money laundering, aiding and abetting, or conspiracy. The Company's activities, and any proceeds thereof, may be considered proceeds of crime due to the fact that cannabis remains illegal federally in the U.S. This may restrict the ability of The Company to declare or pay dividends, effect other distributions or subsequently repatriate such funds back to Canada. Furthermore, while The Company has no current intention to declare or pay dividends on its common shares in the foreseeable future, The Company may decide or be required to suspend declaring or paying dividends without advance notice and for an indefinite period of time.

US State regulation overview

Oregon

The State passed the "Control, Regulation, and Taxation of Marijuana and Industrial Hemp Act" in November 2014, which created the framework for people over the age of 21 purchase cannabis, as well as cultivate at home. The regulatory body that oversees these businesses is the Oregon Liquor and Control Commission ("OLCC"), which enacted rules that commenced in June 2016 known as Division 25 of the Oregon Administrative Rules Division ("OAR Division 25"). There currently is no limit on the number of licenses being issues.

The latest Federal memorandum was issued in May, 2018 by Attorney Williams for priorities to combat illicit cannabis operators. One major issue was the oversupply crossing state borders which is still Federally illegal. Other items included to combat cultivation that threaten federal land, selling to minors, and unlicensed producers. The Company has not found any other statements made by Federal authorities in this State.

California

California was the first State to pass a medical marijuana law for medicinal use in 1996. However, it wasn't until September of 2015 when it passed the "Medical Cannabis Regulation and Safety Act" ("MCRSA") to establish licensing and regulations for this purpose. Later, in November 2016, the "Adult Use of Marijuana Act" ("AUMA") was enacted to tax and regulate use for adults over the age of 21 years of age.

In June 2017, the "Medical and Adult-Use Cannabis Regulation and Safety Act" ("MAUCRSA") passed the Senate, which combined the MCRSA and AUMA to regulate all cannabis use in the State. Later in November 2017, California introduced regulations which were to be governed by the California Bureau of Cannabis Control ("BCC"), California Department of Public Health and California Department of Food and Agriculture to provide further clarity on legalizing cannabis. These took effect on January 2018 when California fully legalized cannabis use.

Current rules imply cannabis operators must first be obtain local approval, as each locality governs what is prohibited in their jurisdiction. Once approved, the operator may apply for a State license, in which there currently is no limit in California. The only current stipulation is that of testing laboratories, which may not hold any other license.

The latest Federal statement was issued in May, 2018 by Attorney McGregor Scott, which provided \$2.5 million in federal funds to combat illicit cannabis operators, while defending regulation of licit cannabis. The Company has not found any other statements made by Federal authorities in this State.

Nevada

Nevada legalized medicinal use of marijuana in 2001, but it wasn't until 2015 that state-certified dispensaries became operational, which is governed by the Nevada Revised Statute ("NRS") 453A. This statute sets out the licensing and operational requirements for distribution and production of medicinal cannabis. Later in November 2016, sale of cannabis for adult use was set out by NRS 453A, which exempts a person who is 21 or older from state and local prosecution.

As of July 2017, the Nevada Department of Taxation ("NDT") became responsible for licensing and regulating cannabis businesses and the state medicinal program. For medicinal establishments, each must register with the NDT,

as well as all people who work and volunteer there. Among some of the requirements are minimum liquidity and restrictions on locations. These certificates expire every year and must be renewed. For recreational use, medical dispensaries can now have dual licenses. For strictly recreational dispensaries, locations are determined by county size.

Nevada Attorney General Adam Laxalt vehemently defends the cannabis state law since it was approved by the voters, making various statements against the Sessions Memorandum. Governor Brian Sandoval also continues to promote legalized cannabis since it was approved in 2016. Neither of these individuals are a federal authority or prosecutor, but their actions provide a good indication of the support for the cannabis industry in this State. US Attorney for the State of Nevada is Dayle Elieson, who has not clearly or publicly indicated her position on the Sessions Memorandum. The Company has not found any other recent statements made by Federal authorities in this State.

The Company's Investments in the Cannabis Industry (other than those operating in the U.S.)

The Company has invested in R&D Pharma Corp. as disclosed above.

The Company has also invested in a minority interest (<1%) of Khiron Life Sciences Corp., a Canadian TSXV-listed medical cannabis company with its core operations in Colombia with a focus on developing and commercializing top quality medically-validated products and other pharmaceutical products.

The Company has also invested in a minority interest (<1%) of ThreeD Capital Corp., a Canadian CSE-listed venture capital company focused on opportunistic investments in companies in the Junior Resources, Artificial Intelligence and Blockchain sectors that also has investments in the legal cannabis sector.

Heightened Scrutiny and Canadian Securities Regulatory Matters

For the reasons set forth above, the Company's activities (investing in companies that operate in the U.S. or possible future sales of its own products in the U.S.) in the U.S. may become the subject of heightened scrutiny by regulators, stock exchanges and other authorities in Canada. As a result, the Company may be subject to significant direct and indirect interaction with public officials. There can be no assurance that this heightened scrutiny will not in turn lead to the imposition of certain restrictions on the Company's activities in the U.S. or any other jurisdiction, in addition to those described herein.

On February 8, 2018, following discussions with the Canadian Securities Administrators and recognized Canadian securities exchanges, the TMX Group announced the signing of a Memorandum of Understanding ("MOU") with Aequitas NEO Exchange Inc., the CSE, the Toronto Stock Exchange, and the TSX Venture Exchange. The MOU outlines the parties' understanding of Canada's regulatory framework applicable to the rules, procedures, and regulatory oversight of the exchanges and CDS as it relates to issuers with cannabis-related activities in the U.S. The MOU confirms, with respect to the clearing of listed securities, that CDS relies on the exchanges to review the conduct of listed issuers. As a result, there is no CDS ban on the clearing of securities of issuers with cannabis related activities in the U.S. However, there can be no guarantee that this approach to regulation will continue in the future. If such a ban were to be implemented, it would have a material adverse effect on the ability of holders of common shares of The Company to make and settle trades. In particular, The Company common shares would become highly illiquid because until an alternative was implemented, investors would have no ability to effect a trade of such shares through the facilities of a Canadian stock exchange.

Regulatory Framework and Risks Relating to Cannabis in Canada

Summary of the Cannabis Act and Regulations

On December 13, 2016, the Task Force on Cannabis Legalization and Regulation (the "Task Force"), which was established by the Canadian Federal Government to seek input on the design of a new system to legalize, regulate and restrict access to cannabis, published its report outlining its recommendations. On April 13, 2017, the Canadian Federal Government released Bill C-45, An Act respecting cannabis and to amend the Controlled Drugs and Substances Act, the Criminal Code and other Acts (the "Cannabis Act"), which proposed the enactment of the Cannabis Act (Canada) to regulate the production, distribution and sale of cannabis for unqualified adult use. On November 27, 2017, the House of Commons passed Bill C-45. On June 20, 2018 the Senate approved Bill C-45 and the Act received Royal Assent on June 21, 2018. The Cannabis Act came into force on October 17, 2018. Given that

these regulations are very new, the impact of such regulatory changes on the Corporation's business, future business, and investments is unknown.

The Cannabis Act provides a licensing and permitting scheme for the production, importation, exportation, testing, packaging, labelling, sending, delivery, transportation, sale, possession and disposal of cannabis for nonmedicinal (i.e., adult use) use, to be implemented by regulations made under the Cannabis Act. The Cannabis Act maintains separate access to cannabis for medical purposes, including providing that import and export licenses and permits will only be issued in respect of cannabis for medical or scientific purposes or in respect of industrial hemp.

On July 11, 2018, the Federal Government published regulations in the Canada Gazette, Part II, to support the coming into force of the Cannabis Act, including the Cannabis Regulations ("Cannabis Regulations"), the new Industrial Hemp Regulations ("IHR", and together with the Cannabis Regulations, the "Regulations"), along with proposed amendments to the Narcotic Control Regulations and certain regulations under the Food and Drugs Act (Canada). The Regulations, among other things, outline the rules for the legal cultivation, processing, research, testing, distribution, sale, importation and exportation of cannabis and hemp in Canada, including the various classes of licenses that can be granted, and set standards for cannabis and hemp products that became available for legal sale on October 17, 2018. As of October 17, 2018, the Cannabis Act and Regulations replaced the Access to Cannabis for Medical Purposes Regulation ("ACMPR") as the governing regulations in respect of the production, sale and distribution of medical cannabis and related oil extracts. Transitional provisions of the Cannabis Act provide that every license issued under Section 35 of the ACMPR that was in force immediately before the day on which the Cannabis Act came into force (being October 17, 2018) was deemed to be a licence issued under the Cannabis Act, and that such licence will continue in force until it is revoked or expires.

The Cannabis Regulations establish six classes of licenses:

1. Cultivation licenses;
2. Processing licenses;
3. Analytical testing licenses;
4. Sales for medical purposes licenses;
5. Research licenses; and
6. Cannabis drug licenses.

The Cannabis Regulations also create subclasses for cultivation licenses (standard cultivation, micro-cultivation and nursery) and processing licenses (standard processing and micro-processing). Different licenses and each sub-class therein, carry differing rules and requirements that are intended to be proportional to the public health and safety risks posed by each license category and each sub-class. Producers holding production and sales licenses under the ACMPR will be transferred to similar licenses under the Cannabis Act.

The Cannabis Regulations permit cultivation license holders to conduct both outdoor and indoor cultivation of cannabis, however no licensed activities (except for destruction, antimicrobial treatment and distribution) can take place in a "dwelling-house". The implications of the proposal to allow outdoor cultivation are not yet known, but such a development could be significant as it may reduce start-up capital required for new entrants in the cannabis industry. It may also ultimately lower prices as capital expenditure requirements related to growing outside are typically much lower than those associated with indoor growing.

The new IHR replaced the Industrial Hemp Regulations on October 17, 2018. The regulatory scheme for industrial hemp largely remains the same, however the IHR permits the sale of hemp plants to licensed cannabis producers, and licensing requirements were softened in accordance with the low risk posed by industrial hemp.

Cannabis Tracking System

Under the Cannabis Act, the Minister of Health is authorized to establish and maintain a national cannabis tracking system. The purpose of this system is to track cannabis throughout the supply chain to help prevent diversion of cannabis into, and out of, the legal market. The Cannabis Regulations provide the Minister of Health with the authority to make a ministerial order that would require certain persons named in such order to report specific information about their authorized activities with cannabis, in the form and manner specified by the Minister.

Cannabis Products

The Cannabis Regulations set out the requirements for the sale of cannabis products at the retail level permit the sale of dried cannabis, cannabis oil, fresh cannabis, cannabis plants, and cannabis seeds, including in such forms as "prerolled" and in capsules. The THC content and serving size of cannabis products is limited by the Cannabis Regulations. The sale of edibles containing cannabis and cannabis concentrates will not initially be permitted, however the federal government anticipates that such products will be legalized within one year following the coming into force of the Cannabis Act. The IHR defines industrial hemp as cannabis plants whose leaves and flowering heads do not contain more than 0.3% THC.

Packaging and Labeling

The Cannabis Regulations set out requirements pertaining to the packaging and labelling of cannabis products. Such requirements are intended to promote informed consumer choice and allow for the safe handling and transportation of cannabis. The Cannabis Regulations require all cannabis products to be packaged in a manner that is tamperproof and child-resistant.

While minor allowances for branding would be permitted, Health Canada is proposing strict limits on the use of colours, graphics, and other special characteristics of packaging. Cannabis package labels must include specific information, such as (i) product source information, including the class of cannabis and the name, phone number and email of the cultivator, (ii) a mandatory health warning, rotating between Health Canada's list of standard health warnings; (iii) the Health Canada standardized cannabis symbol; and (iv) information specifying THC and CBD content.

A cannabis product's brand name may only be displayed once on the principal display panel or, if there are separate principal display panels for English and French, only once on each principal display panel. It can be in any font style and any size, so long as it is equal to or smaller than the health warning message. The font must not be in metallic or fluorescent colour. In addition to the brand name, only one other brand element can be displayed.

Cannabis for Medical Purposes

Part 14 of the Cannabis Regulations sets out the regime for medical cannabis following legalization, which is to remain substantively the same as that which existed under the ACMPR, with adjustments to create consistency with rules for non-medical use, improve patient access, and reduce the risk of abuse within the medical access system. Patients who have the authorization of their healthcare provider will continue to have access to cannabis, either purchased directly from a federally licensed producer, or by registering to produce a limited amount of cannabis for their own medical purposes, or designating someone to produce cannabis for them.

Under the Part 14 of the Cannabis Regulations, patients have three options for obtaining cannabis for medical purposes: (a) they can continue to access cannabis by registering with Licensed Producers; (b) they can register with Health Canada to produce a limited amount of cannabis for their own medical purposes; or (c) they can designate someone else to produce cannabis for them. With respect to (b) and (c), starting materials, such as marijuana plants or seeds, must be obtained from Licensed Producers. It is possible that (b) and (c) could adversely affect the business, future business, financial condition and results of operations of the Corporation or its investee companies.

Health Products and Cosmetics Containing Cannabis

Health Canada has taken a scientific, evidenced-based approach for the oversight of health products with cannabis that are approved with health claims, including prescription and non-prescription drugs, natural health products, veterinary drugs and veterinary health products, and medical devices. Under the Cannabis Regulations, the use of cannabis-derived ingredients (other than certain hemp seed derivatives containing no more than 10 parts per million THC) in cosmetics is permitted and will be subject to provisions of the Cannabis Act.

Import / Export Permits for Medical or Scientific Purposes

Part 10 of the Cannabis Regulations sets of the process by which a license holder may apply for an import or export permit for medical or scientific purposes, as set out in the regulations. A permit must be obtained for each shipment

of cannabis. An application for an import or export permit must contain specific information including the name and address of the holder, license number and specifics of the particular shipment including intended use of the cannabis and specific shipment details. The Cannabis Regulations contain reporting requirements in respect of the import / export of cannabis in reliance of a permit issued under the Cannabis Regulations.

Provincial and Territorial Regulatory Framework for Recreational Cannabis

While the Cannabis Act provides for the regulation of the commercial production of cannabis for recreational purposes and related matters by the federal government, the Cannabis Act proposes that the provinces and territories of Canada will have authority to regulate other aspects of recreational cannabis (similar to what is currently the case for liquor and tobacco products), such as sale and distribution, minimum age requirements, places where cannabis can be consumed, and a range of other matters.

All Canadian provinces and territories have announced proposed regulatory regimes for the distribution and sale of cannabis for recreational purposes within those jurisdictions. Each of these Canadian jurisdictions has established a minimum age of 19 years old, except for Québec and Alberta, where the minimum age is 18.

Additional cannabis-related risk factors in Canada

The Company, or its subsidiaries or investee companies, may be subject to product liability claims or regulatory action if its products are alleged to have caused significant loss or injury. This risk is exacerbated by the fact that cannabis use may increase the risk of serious adverse side effects.

The Company may not be able to obtain adequate insurance coverage in respect of the risks, the premiums for such insurance may not continue to be commercially justifiable or there may be coverage limitations and other exclusions which may result in such insurance not being sufficient to cover potential liabilities.

The laws, regulations and guidelines generally applicable to the medical cannabis industry in Canada and other countries may change in ways that impact the Company's ability to continue its business as currently conducted or proposed to be conducted. The successful execution of any future cannabis-related business objectives is contingent upon compliance with all applicable laws and regulatory requirements in Canada and other jurisdictions, and obtaining all other required regulatory approvals for the development, production, sale, import and export of our medical cannabis products. Failure to comply with applicable regulations or good manufacturing processes could prevent the Company or its investee companies from being able to carry on their business or execute future business plans.

The Company, through its investments, and some of its investee companies are dependent upon regulatory approvals and licenses for their ability to grow, process, package, store, sell and export medical cannabis and other products derived therefrom, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal. There can be no assurance that required licenses will be obtained, nor can there be any assurance that the Canadian government will continue to issue export permits on the same terms, or that other countries will allow, or continue to allow, imports.

As well, the legal landscape for medical and recreational cannabis is changing internationally. More countries have passed laws that allow for the production and distribution of cannabis for medical purposes in some form or another. Increased international competition and/or limitations placed on the Company by Canadian regulators may impact the financial performance of the Company. The Company may seek to expand its business and operations into jurisdictions outside of Canada and the U.S. and there are risks associated with doing so and there can be no assurance that any market for The Company's products will develop in any such foreign jurisdiction. The Company may face new or unexpected risks or significantly increase its exposure to one or more existing risk factors, including economic instability, changes in laws and regulations and the effects of competition. These factors may limit the Company's capability to successfully expand its operations and may have a material adverse effect on the Company's business, financial condition and results of operations.

Corporate Governance Practices

The disclosure required pursuant to National Instrument 58-101-Disclosure of Corporate Governance Practices was made by the Corporation in its Management Information Circular which was mailed to shareholders and is accessible via the Internet for public viewing on the System for Electronic Document Analysis and Retrieval at www.sedar.com.

Critical Accounting Estimates

The preparation of financial statements in accordance with IFRS requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amount of revenues and expenses during the reported year. Actual results could differ from those estimates.

Other Information

The Corporation's website address is www.belgraviacapital.ca. Other information relating to the Corporation may be found on SEDAR at www.sedar.com.